Kestra Advisory Services LLC Has $48.36 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Kestra Advisory Services LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 334,387 shares of the company’s stock after selling 12,656 shares during the quarter. Kestra Advisory Services LLC’s holdings in Johnson & Johnson were worth $48,359,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Buckley Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 5.1% during the 4th quarter. Buckley Wealth Management LLC now owns 61,241 shares of the company’s stock worth $8,857,000 after purchasing an additional 2,972 shares in the last quarter. Greatmark Investment Partners Inc. boosted its stake in Johnson & Johnson by 7.8% in the 4th quarter. Greatmark Investment Partners Inc. now owns 112,237 shares of the company’s stock valued at $16,232,000 after buying an additional 8,075 shares in the last quarter. HMV Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at $442,000. First National Trust Co boosted its stake in Johnson & Johnson by 0.3% in the 4th quarter. First National Trust Co now owns 150,980 shares of the company’s stock valued at $21,835,000 after buying an additional 511 shares in the last quarter. Finally, Brown Miller Wealth Management LLC boosted its stake in Johnson & Johnson by 2.9% in the 4th quarter. Brown Miller Wealth Management LLC now owns 20,242 shares of the company’s stock valued at $2,927,000 after buying an additional 569 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Citigroup decreased their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Barclays boosted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Finally, Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Trading Down 0.0 %

NYSE JNJ opened at $162.94 on Friday. The stock has a 50-day simple moving average of $154.98 and a 200 day simple moving average of $156.37. The company has a market capitalization of $392.29 billion, a PE ratio of 24.50, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.29 earnings per share. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.